Dyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1
(RTTNews) - Dyne Therapeutics, Inc. (DYN) Friday announced encouraging data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1). Myotonic dystrophy type 1 is a genetic disease that causes progressive muscle weakness and loss.
In recent years, a growing understanding of myotonic dystrophy type 1 (DM1)—an often fatal, devastating, rare neuromuscular disorder that causes muscle weakness and other life-limiting ...
AOC 1001 for myotonic dystrophy type 1 (DM1) – within the next few months. DM1 (formerly known as Steinert disease) is caused by a defect in the DMPK gene on chromosome 19 and is a form of ...
Patients with myotonic dystrophy have smaller hearts, and lower systolic and diastolic blood pressures and pulse rates. They have impaired autonomic reflexes, measured by orthostatic, Valsalva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback